Inside informationEnglish
Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 18/04/2026, 12:00
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 116496_20260418